CBP501 Increases Efficiency Of Pemetrexed And Cisplatin, Providing New Option For Relapsed Patients

CBP501 is a drug that increases the cytotoxicity of DNA-damaging anticancer drugs against cancer cells without increasing adverse effects. In this study, CBP501 will be combined with Pemetrexed and Cisplatin. I like this approach because it increases the efficiency of Pemetrexed and Cisplatin and it provides a new option for patients that have progressed after previous treatments. Click on the following link to participate in this clinical trial.
Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II).

Speak Your Mind